Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 91-100 of 236 for multiple myeloma

Edit search filters
  1. Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  2. A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  3. GPRC5D-directed CAR T Cell Therapy In Participants With Relapsed Or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  6. Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

    Rochester, MN

  7. Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  8. A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  9. S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

    Jacksonville, FL, Rochester, MN

  10. A Study to Compare the Effectiveness and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer